Literature DB >> 16225172

Clinical and biochemical heterogeneity in an Italian family with CPT II deficiency due to Ser 113 Leu mutation.

Mubeen F Rafay1, E Gordon Murphy, J Denis McGarry, Petra Kaufmann, Salvatore DiMauro, Ingrid Tein.   

Abstract

BACKGROUND: Carnitine palmitoyltransferase II (CPT II) deficiency is an autosomal recessive disorder which presents with recurrent myoglobinuria. Heterozygotes are usually asymptomatic.
METHODS: We correlate the clinical, biochemical and molecular features of a family in which the proband is homozygous for CPT II deficiency, due to the common Ser 113 Leu mutation.
RESULTS: The 20-year-old female proband presented at age three years with episodic myalgia and myoglobinuria, elevated creatine kinase (CK) of 3600 IU/L and had a 33% residual CPT II activity in cultured skin fibroblasts. Her 25-year-old dizygotic twin brothers presented with muscle stiffness following prolonged exercise but no overt pigmenturia and had interictal CKs up to 662 lU/L. Her parents and a 13-year-old brother are asymptomatic. An elder sister, not investigated, had recurrent pigmenturia and died at eight years with myoglobinuria. Molecular analysis revealed that the proband is homozygous for the Ser 113 Leu mutation. Her parents are heterozygotes with CPT II activities of 55% to 70%. Her younger brother is normal with 83% activity. The symptomatic twin brother are heterozygous but demonstrated unexpectedly low CPT II activities of 40%, which may explain their phenotype.
CONCLUSION: We postulate that there may be genetic, environmental and sex hormonal factors accounting for this manifesting heterozygosity and biochemical heterogeneity in CPT II deficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225172     DOI: 10.1017/s0317167100004194

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  3 in total

Review 1.  Carnitine palmitoyltransferase II deficiency with a focus on newborn screening.

Authors:  Go Tajima; Keiichi Hara; Miori Yuasa
Journal:  J Hum Genet       Date:  2018-12-04       Impact factor: 3.172

2.  Clinically symptomatic heterozygous carnitine palmitoyltransferase II (CPT II) deficiency.

Authors:  Pushpa Raj Joshi; Marcus Deschauer; Stephan Zierz
Journal:  Wien Klin Wochenschr       Date:  2012-11-27       Impact factor: 1.704

3.  Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development.

Authors:  Ivan Shelihan; Elsa Rossignol; Jean-Claude Décarie; Jean-Paul Bonnefont; Michèle Brivet; Catherine Brunel-Guitton; Grant A Mitchell
Journal:  JIMD Rep       Date:  2021-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.